


PHARMACEUTICAL 2020

GERON CORP Rank 156 of 362









PHARMACEUTICAL 2020

≬geron

GERON CORP Rank 156 of 362

The relative strengths and weaknesses of GERON CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GERON CORP compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 174% points. The greatest weakness of GERON CORP is the variable Research and Development, reducing the Economic Capital Ratio by 88% points.

The company's Economic Capital Ratio, given in the ranking table, is -131%, being 172% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	141,608
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,162
Liabilities, Non-Current	0
Other Assets	23,501
Other Compr. Net Income	315
Other Expenses	69
Other Liabilities	0
Other Net Income	-195
Property and Equipment	408
Research and Development	52,072
Revenues	4,681
Selling, General and Administrative Expense	20,893

Output Variable	Value in 1000 USD
Assets	165,517
Liabilities	28,162
Expenses	73,034
Stockholders Equity	137,355
Net Income	-68,548
Comprehensive Net Income	-68,390
Economic Capital Ratio	-131%

